ArticleInternational ophthalmology2026
One-year follow-up of implantable Collamer lens in myopic patients.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the outcomes of Evolution (EVO) Implantable Collamer Lens (ICL) V4c implantation in patients with high myopia, emphasizing the enhancement of visual acuity, refractive error correction, and ocular health parameters.
methodsThe study sample included 91 eyes of 52 patients with high myopia (Preoperative spherical equivalent (SE) ≤ - 5 diopters (D)) who underwent EVO ICL V4c implantation between 2017 and 2020. Data were collected preoperatively and at one, six, and 12 months postoperatively. Evaluated parameters included uncorrected and corrected distance visual acuity (UDVA and CDVA), spherical equivalent (SE), sphere power, cylinder power, intraocular pressure (IOP), endothelial cell density (ECD), central corneal thickness (CCT), and anterior chamber measurements. A statistically significant difference was defined as p < 0.05.
resultsA total of 91 eyes from 52 patients were included. Longitudinal mixed-effects modeling demonstrated significant postoperative changes in visual acuity, refractive error, and anterior segment parameters throughout follow-up (all over p < .001). Mean spherical equivalent improved from - 8.23 ± 3.65 D preoperatively to - 0.82 D at 12 months, while UDVA improved from 1.08 ± 0.22 to 0.089 logMAR At 12 months, 64.4% of eyes were within ± 1.00 D of emmetropia, and 100% of eyes remained within ± 1.00 D of SE change between 6 and 12 months. Mean endothelial cell density loss was 1.24 ± 3.80%, and no eyes developed pathological IOP elevation (> 21 mmHg). No eyes lost ≥ 2 lines of CDVA, while 20.0% gained ≥ 2 lines. The safety and efficacy indices were 1.17 ± 0.31 and 1.05 ± 0.29, respectively.
conclusionEVO ICL V4c implantation is a safe and effective procedure for correcting high myopia, providing significant and sustained improvement in visual and refractive outcomes with favorable safety, refractive stability, and acceptable postoperative anatomical changes during one year of follow-up.
Indexed as
Identifiers
42560419What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.